The Predictive Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention

References

• Giacoppo D, Madhavan MV, Baber U, et al. Impact of contrast-induced acute kidney injury after percutaneous coronary intervention on short- and long-term outcomes: pooled analysis from the HORIZONS-AMI and ACUITY Trials. Circ Cardiovasc Interv. 2015;8(8):e002475. doi:10.1161/CIRCINTERVENTIONS.114.002475
   PubMed Web of Science ®Google Scholar
• Fliser D, Laville M, Covic A, et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant. 2012;27:4263–4272.
   PubMed Web of Science ®Google Scholar
• Weisbord SD, Chen H, Stone RA, et al. Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography. J Am Soc Nephrol. 2006;17:2871–2877.
   PubMed Web of Science ®Google Scholar
• James MT, Ghali WA, Tonelli M, et al. Acute kidney injury following coronary angiography is associated with a long-term decline in kidney function. Kidney Int. 2010;78:803–809.
   PubMed Web of Science ®Google Scholar
• Amin AP, Bach RG, Caruso ML, Kennedy KF, Spertus JA. Association of variation in contrast volume with acute kidney injury in patients undergoing percutaneous coronary intervention. JAMA Cardiol. 2017;2:1007–1012.
   PubMed Web of Science ®Google Scholar
• Jaroszyński A, Zaborowski T, Głuszek S, et al. Heat shock protein 27 is an emerging predictor of contrast-induced acute kidney injury on patients subjected to percutaneous coronary interventions. Cells. 2021;10:684.
   PubMed Web of Science ®Google Scholar
• Seibert FS, Heringhaus A, Pagonas N, et al. Dickkopf-3 in the prediction of contrast media induced acute kidney injury. J Nephrol. 2021;34:821–828.
   PubMed Web of Science ®Google Scholar
• Hahm E, Wei C, Fernandez I, et al. Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease. Nat Med. 2017;23:100–106.
   PubMed Web of Science ®Google Scholar
• Luo S, Coresh J, Tin A, et al. Soluble urokinase-type plasminogen activator receptor in black Americans with CKD. Clin J Am Soc Nephrol. 2018;13:1013–1021.
   PubMed Web of Science ®Google Scholar
• Hodges GW, Bang CN, Wachtell K, Eugen-Olsen J, Jeppesen JL. suPAR: a new biomarker for cardiovascular disease? Can J Cardiol. 2015;31:1293–1302.
   PubMed Web of Science ®Google Scholar
• Backes Y, van der Sluijs KF, Mackie DP, et al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med. 2012;38:1418–1428.
   PubMed Web of Science ®Google Scholar
• Jhee JH, Nam BY, Lee CJ, et al. Soluble urokinase-type plasminogen activator receptor, changes of 24-hour blood pressure, and progression of chronic kidney disease. J Am Heart Assoc. 2021;10:e017225.
   PubMed Web of Science ®Google Scholar
• Hayek SS, Sever S, Ko YA, et al. Soluble urokinase receptor and chronic kidney disease. N Engl J Med. 2015;373:1916–1925.
   PubMed Web of Science ®Google Scholar
• Sehestedt T, Lyngbæk S, Eugen-Olsen J, et al. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events. Atherosclerosis. 2011;216:237–243.
   PubMed Web of Science ®Google Scholar
• Mossanen JC, Pracht J, Jansen TU, et al. Elevated soluble urokinase plasminogen activator receptor and proenkephalin serum levels predict the development of acute kidney injury after cardiac surgery. Int J Mol Sci. 2017;18:1662.
   PubMed Web of Science ®Google Scholar
• Dande RR, Peev V, Altintas MM, Reiser J. Soluble urokinase receptor and the kidney response in diabetes mellitus. J Diabetes Res. 2017;2017:3232848.
   PubMed Web of Science ®Google Scholar
• Hayek SS, Leaf DE, Samman Tahhan A, et al. Soluble urokinase receptor and acute kidney injury. N Engl J Med. 2020;382:416–426.
   PubMed Web of Science ®Google Scholar
• Nijssen EC, Rennenberg RJ, Nelemans PJ, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, Phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017;389:1312–1322.
   PubMed Web of Science ®Google Scholar
• Ronco F, Tarantini G, McCullough PA. Contrast induced acute kidney injury in interventional cardiology: an update and key guidance for clinicians. Rev Cardiovasc Med. 2020;21:9–23.
   PubMed Web of Science ®Google Scholar
• Parikh CR, Liu C, Mor MK, et al. Kidney biomarkers of injury and repair as predictors of contrast-associated AKI: a substudy of the PRESERVE trial. Am J Kidney Dis. 2020;75:187–194.
   PubMed Web of Science ®Google Scholar
• Mehran R, Dangas GD, Weisbord SD. Contrast-associated acute kidney injury. N Engl J Med. 2019;380:2146–2155.
   PubMed Web of Science ®Google Scholar
• Mamoulakis C, Tsarouhas K, Fragkiadoulaki I, et al. Contrast-induced nephropathy: basic concepts, pathophysiological implications and prevention strategies. Pharmacol Ther. 2017;180:99–112.
   PubMed Web of Science ®Google Scholar
• Pistolesi V, Regolisti G, Morabito S, et al. Contrast medium induced acute kidney injury: a narrative review. J Nephrol. 2018;31:797–812.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Shao X, Jiang N, et al. Caspase-11-mediated tubular epithelial pyroptosis underlies contrast-induced acute kidney injury. Cell Death Dis. 2018;9:983.
   PubMed Web of Science ®Google Scholar
• Lau A, Chung H, Komada T, et al. Renal immune surveillance and dipeptidase-1 contribute to contrast-induced acute kidney injury. J Clin Invest. 2018;128:2894–2913.
   PubMed Web of Science ®Google Scholar
• Rasmussen LJ, Ladelund S, Haupt TH, et al. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study. Emerg Med J. 2016;33:769–775.
   PubMed Web of Science ®Google Scholar
• Desmedt S, Desmedt V, Delanghe JR, Speeckaert R, Speeckaert MM. The intriguing role of soluble urokinase receptor in inflammatory diseases. Crit Rev Clin Lab Sci. 2017;54:117–133.
   PubMed Web of Science ®Google Scholar
• Theilade S, Lyngbaek S, Hansen TW, et al. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes. J Intern Med. 2015;277:362–371.
   PubMed Web of Science ®Google Scholar
• Hessol NA, Schneider M, Greenblatt RM, et al. Retention of women enrolled in a prospective study of human immunodeficiency virus infection: impact of race, unstable housing, and use of human immunodeficiency virus therapy. Am J Epidemiol. 2001;154:563–573.
   PubMed Web of Science ®Google Scholar
• Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011;17:952–960.
   PubMed Web of Science ®Google Scholar
• Maile LA, Busby WH, Gollahon KA, et al. Blocking ligand occupancy of the αVβ3 integrin inhibits the development of nephropathy in diabetic pigs. Endocrinology. 2014;155:4665–4675.
   PubMed Web of Science ®Google Scholar
• Delville M, Sigdel TK, Wei C, et al. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med. 2014;6:256ra136.
   PubMed Web of Science ®Google Scholar
• Yoo TH, Pedigo CE, Guzman J, et al. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease. J Am Soc Nephrol. 2015;26:133–147.
   PubMed Web of Science ®Google Scholar
• Iversen E, Houlind MB, Kallemose T, et al. Elevated suPAR is an independent risk marker for incident kidney disease in acute medical patients. Front Cell Dev Biol. 2020;8:339.
   PubMed Web of Science ®Google Scholar
• Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25:1822–1832.
   PubMed Web of Science ®Google Scholar
• Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. J Med Virol. 2008;80:209–216.
   PubMed Web of Science ®Google Scholar